首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >A selective and sensitive stability-Indicating HPLC method for the validated assay of etoposide from commercial dosage form and polymeric tubular nanocarriers
【24h】

A selective and sensitive stability-Indicating HPLC method for the validated assay of etoposide from commercial dosage form and polymeric tubular nanocarriers

机译:一种选择性灵敏的指示稳定性的HPLC方法,用于验证来自商业剂型和聚合物管状纳米载体的依托泊苷的含量

获取原文
获取原文并翻译 | 示例
           

摘要

Etoposide is a topoisomerase II enzyme inhibitor type chemotherapeutic agent which is widely used in the therapy of various cancers. Its short half-life and toxicity to normal tissues are the major drawbacks in its clinical applications. Polymeric nanoparticulate drug delivery systems are rational carriers to deliver etoposide with higher efficiency and fewer side effects. In addition tubular shaped drug carriers are found to show a great potential for drug delivery on the basis of promising results regarding particle shape and cellular uptake. In this study, etoposide loaded polymeric tubular nanocarriers have been developed by template wetting method using porous anodic aluminum oxide membranes as templates. The developed poly(methyl methacrylate) nanocarriers were evaluated for structural analysis, in vitro drug release studies and drug release kinetics. Accurate and reliable determination of the drug release from newly developed nanocarriers, is of great importance. For this reason a selective and sensitive reversed phase liquid chromatography method was developed and fully validated from the point of system suitability, specificity, linearity and range, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy and robustness for the reliable determination of etoposide. Stability. indicating capability was shown with forced degradation studies and the chromatographic conditions were optimized on ACE 5C18 (150 mm x 4.6 mm 5 mu m) analytical column. Related to the calibration results ETP was found linear in the range between 0.2 from 100 mu g mL(-1) with the LOD as 0.015 mu g.mL(-1). The resultant conditions were applied for the selective and sensitive determination of etoposide from its commercial dosage form with the high accuracy values (99.82-100.65%). The method was successfully detected assay of etoposide release from newly developed polymeric tubular nanocarriers, which was found as 72.2% at the end of 24 h. (C) 2016 Elsevier B.V. All rights reserved.
机译:依托泊苷是一种拓扑异构酶II酶抑制剂型化学治疗剂,广泛用于治疗各种癌症。其半衰期短和对正常组织的毒性是其临床应用的主要缺点。高分子纳米颗粒药物递送系统是合理的载体,可以以更高的效率和更少的副作用来递送依托泊苷。另外,基于关于颗粒形状和细胞摄取的有希望的结果,发现管状药物载体显示出巨大的药物递送潜力。在这项研究中,已经通过使用多孔阳极氧化铝膜作为模板的模板润湿方法开发了依托泊苷负载的聚合物管状纳米载体。评价了开发的聚甲基丙烯酸甲酯纳米载体的结构分析,体外药物释放研究和药物释放动力学。从新开发的纳米载体中准确可靠地确定药物释放非常重要。因此,开发了选择性灵敏的反相液相色谱方法,并从系统适用性,特异性,线性和范围,检测限(LOD),定量限(LOQ),精密度,准确性和鲁棒性的角度进行了验证。依托泊苷的可靠测定。稳定性。通过强制降解研究显示了指示能力,并在ACE 5C18(150 mm x 4.6 mm 5μm)分析柱上优化了色谱条件。与校准结果相关的ETP在100μgmL(-1)的0.2至0.25μg.mL(-1)的范围内呈线性关系。所得到的条件可用于从依托泊苷的商业剂型中以高准确度(99.82-100.65%)选择性和灵敏地测定依托泊苷。该方法已成功检测到从新开发的聚合物管状纳米载体中释放出的依托泊苷的含量,在24小时结束时发现其含量为72.2%。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号